• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biogen Idec (NQ: BIIB )

    158.01 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 121
    Open 158.01
    Bid (Size) 157.09 (1)
    Ask (Size) 158.72 (1)
    Prev. Close 158.01
    Today's Range 158.01 - 158.01
    52wk Range 153.62 - 268.30
    Shares Outstanding 144,000,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
    UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
    Via Benzinga
    Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
    From Biogen Inc.
    Via GlobeNewswire

    Performance

    YTD
    -40.98%
    -40.98%
    1 Month
    -15.00%
    -15.00%
    3 Month
    -22.29%
    -22.29%
    6 Month
    -27.54%
    -27.54%
    1 Year
    -31.67%
    -31.67%

    More News

    Read More
    Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
    Via Benzinga
    This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
    Via Benzinga
    Peeling Back The Layers: Exploring Biogen Through Analyst Insights
    Via Benzinga
    Evaluating Biogen: Insights From 17 Financial Analysts
    Via Benzinga
    Biogen Analysts Slash Their Forecasts After Q3 Results
    Via Benzinga
    Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
    From Biogen Inc.
    Via GlobeNewswire
    This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
    Via Benzinga
    Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
    From Biogen Inc.
    Via GlobeNewswire
    Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
    Via Investor's Business Daily
    Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
    Via Investor's Business Daily
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Via Benzinga
    Looking Into Biogen's Recent Short Interest
    Via Benzinga
    Biogen (BIIB) Q3 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
    Via Benzinga
    BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
    From Biogen Inc.
    Via GlobeNewswire
    Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
    From Biogen Inc.
    Via GlobeNewswire
    Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
    From Biogen Inc.
    Via GlobeNewswire
    Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
    From Biogen Inc.
    Via GlobeNewswire
    Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
    From Biogen Inc.
    Via GlobeNewswire
    This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
    Via The Motley Fool
    Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
    From Biogen Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.